S&P 500   2,967.82 (-0.08%)
DOW   26,816.30 (0.00%)
QQQ   191.24 (+0.07%)
AAPL   236.53 (+0.13%)
FB   183.43 (-0.41%)
MSFT   139.56 (-0.09%)
CGC   18.84 (-3.04%)
MU   44.89 (-0.47%)
BABA   171.80 (-0.66%)
GE   8.77 (-0.45%)
AMD   30.43 (+2.29%)
T   37.42 (-0.43%)
F   8.81 (+0.34%)
PRI   121.10 (-0.48%)
NFLX   285.50 (+0.91%)
BAC   29.03 (+0.42%)
DIS   129.50 (-0.40%)
S&P 500   2,967.82 (-0.08%)
DOW   26,816.30 (0.00%)
QQQ   191.24 (+0.07%)
AAPL   236.53 (+0.13%)
FB   183.43 (-0.41%)
MSFT   139.56 (-0.09%)
CGC   18.84 (-3.04%)
MU   44.89 (-0.47%)
BABA   171.80 (-0.66%)
GE   8.77 (-0.45%)
AMD   30.43 (+2.29%)
T   37.42 (-0.43%)
F   8.81 (+0.34%)
PRI   121.10 (-0.48%)
NFLX   285.50 (+0.91%)
BAC   29.03 (+0.42%)
DIS   129.50 (-0.40%)
Log in

BIOLINERX LTD/S Stock Price, News & Analysis (NASDAQ:BLRX)

$2.74
-0.04 (-1.44 %)
(As of 10/14/2019 01:43 PM ET)
Today's Range
$2.72
Now: $2.74
$2.76
50-Day Range
$2.56
MA: $2.80
$3.06
52-Week Range
$2.32
Now: $2.74
$22.05
Volume10,839 shs
Average Volume40,400 shs
Market Capitalization$20.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-2548-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.82 per share

Profitability

Net Income$-22,960,000.00

Miscellaneous

Employees51
Market Cap$20.46 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.


BIOLINERX LTD/S (NASDAQ:BLRX) Frequently Asked Questions

What is BIOLINERX LTD/S's stock symbol?

BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX."

How were BIOLINERX LTD/S's earnings last quarter?

BIOLINERX LTD/S (NASDAQ:BLRX) issued its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.61. View BIOLINERX LTD/S's Earnings History.

When is BIOLINERX LTD/S's next earnings date?

BIOLINERX LTD/S is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for BIOLINERX LTD/S.

What price target have analysts set for BLRX?

3 equities research analysts have issued 12-month target prices for BIOLINERX LTD/S's shares. Their predictions range from $3.00 to $10.00. On average, they expect BIOLINERX LTD/S's share price to reach $5.33 in the next year. This suggests a possible upside of 96.1% from the stock's current price. View Analyst Price Targets for BIOLINERX LTD/S.

What is the consensus analysts' recommendation for BIOLINERX LTD/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLINERX LTD/S.

What are Wall Street analysts saying about BIOLINERX LTD/S stock?

Here are some recent quotes from research analysts about BIOLINERX LTD/S stock:
  • 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (10/9/2019)
  • 2. Maxim Group analysts commented, "BioLineRx reported 3Q18 with a net loss of ($6.2M) and ended the quarter with $35M in cash on the balance sheet. We estimate a runway to late 2019." (11/8/2018)

Has BIOLINERX LTD/S been receiving favorable news coverage?

News stories about BLRX stock have been trending negative this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIOLINERX LTD/S earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for BIOLINERX LTD/S.

Are investors shorting BIOLINERX LTD/S?

BIOLINERX LTD/S saw a increase in short interest in September. As of September 15th, there was short interest totalling 70,100 shares, an increase of 10.6% from the August 15th total of 63,400 shares. Based on an average trading volume of 63,400 shares, the short-interest ratio is currently 1.1 days. Currently, 0.7% of the company's stock are sold short. View BIOLINERX LTD/S's Current Options Chain.

Who are some of BIOLINERX LTD/S's key competitors?

What other stocks do shareholders of BIOLINERX LTD/S own?

Who are BIOLINERX LTD/S's key executives?

BIOLINERX LTD/S's management team includes the folowing people:
  • Mr. Philip A. Serlin CPA, MBA, Chief Exec. Officer (Age 59)
  • Ms. Mali Zeevi CPA, Chief Financial Officer (Age 43)
  • Dr. Ella Sorani, VP R&D (Age 51)
  • Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 44)
  • Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 67)

How do I buy shares of BIOLINERX LTD/S?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIOLINERX LTD/S's stock price today?

One share of BLRX stock can currently be purchased for approximately $2.72.

How big of a company is BIOLINERX LTD/S?

BIOLINERX LTD/S has a market capitalization of $20.35 million. The biotechnology company earns $-22,960,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. BIOLINERX LTD/S employs 51 workers across the globe.View Additional Information About BIOLINERX LTD/S.

What is BIOLINERX LTD/S's official website?

The official website for BIOLINERX LTD/S is http://www.biolinerx.com/.

How can I contact BIOLINERX LTD/S?

BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]


MarketBeat Community Rating for BIOLINERX LTD/S (NASDAQ BLRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  437 (Thanks for Voting!)
Underperform Votes:  257 (Thanks for Voting!)
Total Votes:  694
MarketBeat's community ratings are surveys of what our community members think about BIOLINERX LTD/S and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel